Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AZD4512
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of AZD4512 Alone or with Anticancer Agents in Acute Lymphoblastic Leukemia
Details : AZD4512 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 07, 2025
Lead Product(s) : AZD4512
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : D3S-001
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : D3 Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase I Study to Assess Food Effect on Pharmacokinetics of D3S-001 in Healthy Adults
Details : D3S-001 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2025
Lead Product(s) : D3S-001
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : D3 Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AZD5492
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 08, 2025
Lead Product(s) : AZD5492
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Recipient : Italfarmaco
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 10, 2025
Lead Product(s) : Givinostat HCl
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Recipient : Italfarmaco
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Saruparib
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD5305 hADME in Patients With Advanced Solid Malignancies
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Saruparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tezepelumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
November 27, 2024
Lead Product(s) : Tezepelumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : Laroprovstat
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2024
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tezepelumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
June 25, 2024
Lead Product(s) : Tezepelumab
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ATH-1105
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Athira Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 29, 2024
Lead Product(s) : ATH-1105
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Athira Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable